RoC Skincare® Champions Empowered Aging with New Brand Initiative
Leading Clinically-Proven Skincare Brand Launches New Research, Longevity Council, Brown University Research Fund, and continued SeekHer Foundation Community Efforts
NEW YORK, May 21, 2025 /PRNewswire/ -- RoC Skincare® today announces its expanded commitment to empowered aging and supporting the long-term health and vitality of skin. Offering new research about aging perceptions, expert-backed education, advanced clinically-proven skincare technology, and philanthropic efforts, RoC launches its Empowered Aging initiative.Building upon the work RoC established with its Look Forward Project, which spotlighted the benefits of incorporating optimism for longevity, the new initiative offers additional functional, educational and emotional resources to support women's inner and outer vitality. Included in these efforts are the introduction of the RoC Longevity Council, initiation of a research fund to benefit the Center on the Biology of Aging at Brown University, and a continuation of its women's mental health advocacy partnership with the SeekHer Foundation."Optimism and clinically-proven efficacy have been at the core of our brand ethos for years, and these new efforts further our commitment to supporting women through their aging journey," said Hillary Hutcheson, Chief Marketing Officer at RoC Skincare. "Our Empowered Aging initiative equips women at every stage of life with resources to make smarter, proactive choices that can impact longevity and skin health as we get older."New Research on Aging Perceptions & Skincare Product Efficacy For more than six decades, RoC Skincare has been dedicated to empowering women with clinically proven products that enhance skin health and appearance, including its best-selling Line Smoothing Eye Cream. Inspired by the insight that a significant 70% of women report feeling younger than their actual age1, RoC delved further and found that 81% of women feel like the appearance of their skin impacts how they feel emotionally2. With that in mind, RoC conducted a unique study to explore if its popular eye cream could help narrow the gap between women's skin age and the age they feel.In collaboration with a board-certified dermatologist, RoC enlisted eight women to participate in an in-depth study utilizing Visia® Skin imaging to assess changes in apparent eye age after 8 weeks of consistent use of RoC's Line Smoothing Eye Cream. The results demonstrated that 100% of participants experienced an improvement, with some seeing a decrease of up to 7 years in apparent eye age, better aligning their outer appearance with their inner sense of vitality and inspiring optimism about the future. This clinically measured improvement is attributed to RoC Retinol, a potent yet gentle time-released ingredient backed by 27 years of research and 35 patents, delivering continuous results for up to 12 hours. To share the compelling experiences of these women, RoC has launched a new holistic campaign that examines the impact of under-eye appearance on self-perception and perceived age, highlighting the eyes as a key indicator of vitality.
To bring the study to life and in celebration of the launch of its Empowered Aging initiative, RoC Skincare will host a pop-up experience in New York City on June 11-13. Attendees have the opportunity to determine their own True Eye Age with the Visia® Skin Analysis utilized in the study, speak with a dermatologist about their specific eye concerns, receive complimentary full-sized Line Smoothing Eye Cream samples3, win prizes3, and more.
Longevity Council
As the brand expands into a more holistic approach to longevity and well-being, its new Longevity Council will help shape RoC's long-term vision for empowered aging, driving research, community events, and thought leadership in the field. This group of specialists represents a diverse range of aging-related disciplines, from biochemistry to physical health and general wellness, and will serve as key resources, providing education and counsel on new innovation from RoC to support skin longevity. Members include:
Allie Egan, Founder of Veracity
Chris Mirabile, Founder & CEO of NOVOS and Member of the Longevity Biotechnology Association
Florence Comite MD, CEO & Founder Comite Center for Precision Medicine & Healthy Longevity
Dr. Jeanine Downie, MD, Board Certified Dermatology, Image Dermatology PC
Professor John M Sedivy, PhD, Director of the Brown University Center on the Biology of Aging
Yasmine Cheyenne, Self Healing Expert, Author, & Wellness Coach for Today Show's "Start Today"
Research Fund with Brown University
The establishment of the RoC Skincare Longevity Research Fund, gifted to Brown University Center on the Biology of Aging, will fuel groundbreaking research, pave the way for the development of innovative skincare solutions, and contribute valuable knowledge to the broader scientific community.
"We applaud RoC Skincare's vision of a holistic approach to healthy aging, whose goal is to empower all of us to reach our fullest potential," adds Professor John Sedivy, Longevity Council Member. "We are excited to partner with them on catalyzing research on the fundamental biological processes of aging."
Continued SeekHer Foundation Partnership
In a tangible community-based effort to empower women across the country, RoC continues its partnership with the SeekHer Foundation, a non-profit dedicated to women's mental health advocacy, research, and support, via its new Empowered Aging Support Program:
Empowered Aging Guide: Co-branded downloadable step-by-step resource to support women through their Empowered Aging journey
4-Part Virtual Heal & Lead Circles: Facilitated by licensed mental health experts, these themed sessions offer deeper exploration of topics on vibrant living, mindful aging, building strong connections, and finding purpose in their later years, fostering peer engagement
Ongoing Community Resource Access: Monthly reflection prompts centered on women's health and empowered aging, offering the community opportunities to connect, share insights, and offer mutual support
"This year-long initiative is an active commitment to transforming women's experience of aging with optimism and vitality," adds Monica Mo, founder and Executive Director of SeekHer Foundation and WellSeek. "RoC is helping us foster strong communities where shared well-being leads to meaningful personal growth and a stronger network of support for all."
Follow RoC Skincare on Instagram and TikTok @rocskincare to learn more about the Empowered Aging initiative and where NYC locals can visit the "Eyes First" Pop-up Truck.
About RoC Skincare
RoC Skincare has been revolutionizing skincare science since 1957 when Dr. Jean-Charles Lissarrague, a French pharmacist at the Rogé Cavaillès pharmacy, created the first hypoallergenic skincare formulations. RoC has continued to build on its legacy as a brand of firsts, launching the first broad-spectrum UV protection to proactively preserve the health of skin, and the first brand to discover the method for stabilizing Retinol. Collaborating closely with Dermatologists, RoC scientists have spent over 67 years garnering a deep understanding of skin physiology at the cellular level. Today, RoC is at the forefront of dermatological innovation, harnessing cutting-edge technology to achieve over 35 patented breakthroughs in Retinol, Vitamin C, Hyaluronic Acid and Pro Collagen Amino Acids. With over 150 clinical studies, every RoC formula undergoes rigorous clinical testing to prove its high efficacy without any compromises on safety. RoC is 100% hypoallergenic,100% non-comedogenic, PETA-approved, and always clinically proven.
Contact: M Booth at RoCSkincare@mbooth.com
1Study from the University of Virginia, USA on 30,000 subjects2RoC Perksy Study: US, April 20253while supplies last
View original content to download multimedia:https://www.prnewswire.com/news-releases/roc-skincare-champions-empowered-aging-with-new-brand-initiative-302462029.html
SOURCE RoC Skincare
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
21 hours ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.


Business Wire
a day ago
- Business Wire
Foldax Announces Positive One-Year Data on TRIA Mitral Valve
SALT LAKE CITY--(BUSINESS WIRE)--Foldax® Inc., a leader in the development of innovative polymer heart valves, today announced compelling one-year results from the India Clinical Trial of the TRIA™ Mitral Valve, showing a good safety profile, sustained hemodynamic performance, and statistically significant improvement in patient quality of life. These are the first one-year outcomes ever presented for a multicenter clinical study of a polymer heart valve worldwide. Results were presented today at New York Valves 2025, the annual conference organized by the Cardiovascular Research Foundation (CRF), and concurrently published in the Journal of the American College of Cardiology (JACC). 'It is exciting to see the positive clinical outcomes associated with this novel polymer valve.' Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. Share Key one-year results from the trial showed: No valve-related mortality or reinterventions >50% reduction in mean gradient (9.7 mmHg to 4.5 mmHg) and >90% increase in effective orifice area (0.9 cm² to 1.5 cm²), the highest reported in similar surgical mitral valve studies 24-point improvement in KCCQ score (57.5 to 81.9) and 65% increase in Six-Minute Walk Test distance (298.1 m to 494.8 m), indicating significant improvement in quality of life The prospective, multicenter trial enrolled 67 patients aged 19 to 67 across eight sites in India, with an average age of 42. Notably, 64% were women, and of these, nearly half were of childbearing age, a significantly larger percentage than typically seen in clinical studies. Seventy-three percent of patients had rheumatic heart disease. 'It is exciting to see the positive clinical outcomes associated with this novel polymer valve,' said Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. 'This new type of valve sets out to reimagine how a device can address clinical needs that are underserved by current valve solutions.' 'I am proud to be the principal investigator in India for this groundbreaking trial and represent the highly esteemed clinical investigators who participated in the study,' said Kaushal Pandey, M.D., Principal Investigator of the TRIA Mitral Valve India Clinical Trial and Cardiac Surgeon at P.D. Hinduja Hospital in Mumbai. 'The TRIA Mitral Valve provides hope for Indian patients—including younger patients and many women of childbearing age—for whom current valve options often fall short.' Foldax's vision for its novel polymer heart valves is to address the limitations of tissue and mechanical options by making its valves durable, with the future goal of avoiding a requirement for lifelong anticoagulation. TRIA valves incorporate a proprietary polymer—LifePolymer™ —formulated to be calcium-resistant, biostable and biocompatible. The novel polymer material enables TRIA valves to be robotically produced, which is designed to increase manufacturing efficiency and maximize product quality and precision. 'These results validate our strategy of taking heart valve therapy to a new level by bringing innovation to a platform of products that will help patients globally,' said Ken Charhut, CEO of Foldax. The Journal of the American College of Cardiology (JACC) publication can be viewed at: *The TRIA Mitral Valve is approved for use in India by CDSCO. The TRIA Mitral Valve is for investigational use only and is not available for commercial sale in the U.S. Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve—from material to design to manufacturing—to develop surgical and transcatheter valves with the potential to last a lifetime, addressing limitations of tissue and mechanical valves. Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures. For more information on the TRIA Mitral Valve and Foldax's commitment to revolutionizing heart valve care, visit
Yahoo
a day ago
- Yahoo
Cigna Enables Coverage for RhinAer®
Policy Update Validates Clinical Value and Expands Patient Access to Innovative Chronic Rhinitis Treatment MOUNTAIN VIEW, Calif., June 27, 2025--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis. Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna's policy update highlights the growing recognition of RhinAer's clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management. "Cigna's decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients," said Matt Brokaw, CEO of Aerin Medical. "Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition's burden." "Chronic rhinitis takes a substantial toll on patients and Cigna's decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients," said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. "With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna's decision supports the adoption of a therapy that elevates the standard of care for patients." Information for Providers: The codes 31242 - Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve and 31243 - Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve have been removed from experimental / investigational status and will not require precertification. For more information about Cigna's updated medical policy for RhinAer (CPT 31242), visit: About RhinAer Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube. View source version on Contacts Media Contact: Michael FanucchiAerin Medicalmfanucchi@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data